UNIVERSITY HEALTH NETWORK

Their core work

University Health Network (UHN) is one of Canada's largest academic health science centres, combining hospital-based clinical care with translational research. In H2020, they contribute two distinct types of expertise: advanced biophysical characterisation of disease-relevant proteins (using solid-state NMR, solution NMR, and cryo-EM to study tau aggregation in Alzheimer's and related tauopathies), and clinical research methodology focused on standardising how patient-reported outcomes are measured and analysed in oncology and chronic disease trials. Their value to European consortia lies in bridging basic molecular science and large-scale clinical evidence, backed by access to North American patient cohorts and hospital-grade infrastructure.

What they specialise in

How they've shifted over time

UHN's early H2020 engagement (InterTAU, from 2020) is firmly rooted in molecular and structural biology — specifically the biophysics of tau aggregation, using NMR spectroscopy and cryo-EM alongside immunological characterisation of protein-protein interactions. Their second project (SISAQOL-IMI, from 2021) represents a clear pivot toward clinical research infrastructure: the focus shifts from protein structure to patient data quality and measurement standards. With only two projects to read, this is likely not a strategic pivot so much as evidence of two separate research divisions within UHN engaging independently with European networks.

UHN appears to be expanding its European footprint from a single specialist biology role into broader clinical methodology work, suggesting increasing interest in international research standard-setting alongside their established biophysics activity.

How they like to work

UHN has not coordinated any H2020 project, joining exclusively as partner or participant — a pattern consistent with a large institution that engages selectively where it has specific technical or clinical assets to contribute. Despite only two projects, they have accumulated 46 unique consortium partners across 21 countries, which reflects participation in large, multi-partner consortia typical of MSCA-RISE and IMI instruments. This suggests UHN is a sought-after specialist node rather than a consortium builder.

UHN's 46 unique partners across 21 countries — from just two projects — reflects the large consortium structures of MSCA-RISE (staff exchange networks) and IMI (industry-academia partnerships), giving them unusually broad European and global connectivity relative to their project count. Their geographic footprint is firmly international, extending well beyond Europe to include North American and likely Asian partners.

What sets them apart

UHN is one of very few Canadian hospital-based research institutions with direct H2020 participation, which makes them a rare transatlantic bridge: they bring North American clinical cohorts, hospital infrastructure, and regulatory context that pure European academic partners cannot offer. Their combination of deep molecular biology capability (structural proteomics, NMR platforms) and large-scale clinical outcomes expertise within a single institution is uncommon and valuable for consortia that need both bench and bedside credibility.

Highlights from their portfolio

• InterTAU
  A five-year MSCA-RISE network applying three complementary biophysical techniques (solid-state NMR, solution NMR, cryo-EM) to map tau pathology — one of the most technically demanding structural biology targets in neurodegeneration research.
• SISAQOL-IMI
  An IMI-funded initiative to establish international statistical standards for patient-reported outcome data, with direct regulatory and clinical trial design implications across the European pharma industry.